Brief Description
Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1,000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The Singulex Clarity system and Singulex Clarity assay received CE mark in 2017 and are commercially available in Europe; additional assays to detect and rule out infectious and inflammatory diseases are in development. Singulex is also developing a point-of-care platform and exploring applications beyond the clinical setting. Singulex ceased operations in June 2019.
Formerly known as BioProfile Corporation
Timeline
- 2003. Company founded.
- 2015. Singulex's core technology, called single molecule counting (SMC) was acquired along with the firm's life science business by MilliporeSigma in 2015 and incorporated into the SMCxPRO system.